|Bid||118.48 x 0|
|Ask||118.52 x 0|
|Day's Range||117.50 - 120.00|
|52 Week Range||110.97 - 199.40|
|Beta (5Y Monthly)||0.53|
|PE Ratio (TTM)||19.22|
|Earnings Date||Apr 26, 2021|
|Forward Dividend & Yield||0.10 (0.09%)|
|Ex-Dividend Date||Jul 07, 2020|
|1y Target Est||100.77|
The Chinese government has made an investment in BGI Genomics Co, a listed Chinese company that has supplied millions of COVID-19 tests globally as the gene firm seeks to fund exponential growth driven by the pandemic. BGI Group, which runs a massive gene databank in China and has DNA sequencing contracts with health firms and universities worldwide, has in the past responded to claims from U.S. security agencies that it is closely linked to the Chinese government by saying it has no Chinese government capital. BGI Genomics, the company's subsidiary listed on the Shenzhen stock exchange, raised the equivalent of just over $300 million in a private placement to investors including China's biggest state investment vehicle, the State Development and Investment Corp (SDIC), filings to the exchange on Feb. 1 show.
China's BGI Genomics Co said on Tuesday it expects first-half net profit to be about eight times the amount reported in the same period last year after the global pandemic created a surge in demand for its coronavirus test kits. The genomics company, which said it has distributed more than 35 million kits across 180 countries and regions, forecasted a net profit of between 1.53 to 1.63 billion yuan ($218.32-$232.66 million) in the six months to end-June, a jump of around 700% from 198 million yuan a year ago. The novel coronavirus, which first emerged in China late last year, has to date infected over 13 million people globally and killed more than 575,000.